findmyKOL
Clinical trialNCT05592015RecruitingPhase 2Interventional

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

SponsorJonathan BrammerEnrollment30T-Cell Large Granular Lymphocyte Leukemia
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell large granular lymphocyte leukemia. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Jonathan Brammer, MD

    Ohio State University Comprehensive Cancer Center

    Principal Investigator
    clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

    Eric Jacobsen, MD
    Recruiting
  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

    Alison Moskowitz, MD
    Recruiting
  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, United States

    Jonathan Brammer, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ruxolitinib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
3 May 2023
Primary completion
31 Jul 2026
Completion
31 Jul 2026
Last update posted
10 Feb 2026
Registered enrollment
30
Registry id
NCT05592015
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.